
    
      Samples will be collected from 4 groups of patients with HIV/HCV infection, identified by the
      virologic control of either HIV, HCV, or both. Sera will be used in an in-vitro hepatocyte
      model of hepatitis C infection to better understand the pathogenesis of HIV/HCV co-infection,
      and to gain insight into intracellular mechanisms.
    
  